Editas Medicine (NASDAQ:EDIT) and Axcella Health (NASDAQ:AXLA) Financial Analysis

Editas Medicine (NASDAQ:EDIT) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Institutional and Insider Ownership

75.4% of Editas Medicine shares are held by institutional investors. 0.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


This table compares Editas Medicine and Axcella Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Editas Medicine -359.93% -47.64% -27.40%
Axcella Health N/A N/A N/A

Analyst Ratings

This is a summary of current ratings and target prices for Editas Medicine and Axcella Health, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Editas Medicine 0 3 6 0 2.67
Axcella Health 0 0 4 0 3.00

Editas Medicine currently has a consensus price target of $40.25, indicating a potential upside of 76.30%. Axcella Health has a consensus price target of $22.00, indicating a potential upside of 121.11%. Given Axcella Health’s stronger consensus rating and higher probable upside, analysts plainly believe Axcella Health is more favorable than Editas Medicine.

Valuation and Earnings

This table compares Editas Medicine and Axcella Health’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Editas Medicine $31.94 million 35.18 -$109.95 million ($2.33) -9.80
Axcella Health N/A N/A -$36.07 million N/A N/A

Axcella Health has lower revenue, but higher earnings than Editas Medicine.


Axcella Health beats Editas Medicine on 6 of the 10 factors compared between the two stocks.

Editas Medicine Company Profile

Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Axcella Health Company Profile

There is no company description available for Axcella Health Inc.

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit